High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Inclusion Criteria: * Ability to provide informed consent * Karnofsky Performance Status (KPS) \>= 70 * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Availability of a suitable allogeneic hematopoietic stem cell donor; minimum of human leukocyte antigen (HLA) 7/8 matched related or unrelated donor * High risk multiple myeloma with poor prognostic features based on having one or more of the following criteria: * Progressive disease after autologous transplant. No less than 3 months post auto transplant * Progressive or stable disease after induction chemotherapy using the most potent myeloma agents Lenalidomide and/or Bortezomib * Patients with high risk cytogenetic abnormalities documented on conventional cytogenetics or fluorescence in situ hybridization (FISH) (hypodiploidy, t(4:14), t(14:16) chromosome translocation, p53 and or complex cytogenetics) additionally, chromosome 13 deletion by standard cytogenetics * Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test for women, as well as implementation of birth control for men and women Exclusion Criteria: * Patients with prior allogeneic transplant, or more than one prior autologous transplant for any medical reason * Prior treatment with busulfan or gemtuzumab (Mylotarg ®) for any reason * Patient with history of allergy to boron, mannitol, or bortezomib * Creatinine clearance (CrCl) =\< 50 ml/min * Ejection Fraction \< 50% * Diffusion capacity of carbon monoxide (DLCO) \< 50% predicted * Forced expiratory volume in 1 second (FEV1) \< 50% predicted * Forced vital capacity (FVC) \< 50% predicted * Patients with uncontrolled arrhythmia or uncontrolled heart disease at the screening time; patients with coronary heart disease (recent myocardial infarctions, angina, cardiac stent, or bypass surgery in the last 6 months) need to be cleared with a stress echo or nuclear myocardial perfusion stress test, and cardiology consult; all other cardiac history will be at the discretion of the principal investigator * Liver enzymes \> 3 times upper limit normal * Bilirubin \> 2 mg/dl (except Gilbert's disease) * International normalized ratio (INR) \> 2 * Any previous history of liver failure, hepatitis, or cirrhosis * Systemic Amyloidosis Known history of hepatitis B, C, human immunodeficiency virus (HIV) or any current uncontrolled infection * Grade \> I neuropathy * Women who are pregnant or lactating * Current or history of alcohol or drug abuse * Use of other investigational agents within 30 days of enrollment to this study * Any patient with ascites * Any patient on home oxygen * Any clinical findings on history or physical exam which would in the opinion of the treating physician or principal investigator preclude the patient from participating in the study